Transmedics Group Inc (TMDX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
CEO:
Waleed H. Hassanein
Employees:
200 MINUTEMAN ROAD, ANDOVER, MA 01810
9785520900

Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. The company offers its products in the United States and internationally. Transmedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 875.209 Million Shares Outstanding27.962 Million Avg 30-day Volume 214.723 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.68
Price to Revenue17.4852 Debt to Equity0.5187 EBITDA-37.132 Million
Price to Book Value7.7982 Operating Margin-130.2888 Enterprise Value471.884 Million
Current Ratio5.108 EPS Growth-0.379 Quick Ratio4.234
1 Yr BETA 2.21 52-week High/Low 35.37 / 10.0 Profit Margin-146.1073
Operating Cash Flow Growth4.6291 Altman Z-Score0.2314 Free Cash Flow to Firm -25.293 Million
Earnings Report2022-08-04
View SEC Filings from TMDX instead.

View recent insider trading info

Transmedics Group Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TMDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TMDX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-06 by GUNDERSON THOMAS JAMES
  • 4: filed on 2022-06-06 by RAINES MERILEE
  • 4: filed on 2022-06-06 by KANIA EDWIN M JR
  • 4: filed on 2022-06-06 by WEILL DAVID
  • 4: filed on 2022-06-06 by LOVELL STEPHANIE
  • 4: filed on 2022-06-06 by TOBIN JAMES R
  • 4: filed on 2022-06-06 by BASILE EDWARD M
  • 4: filed on 2022-06-03 by CAREY JOHN F
  • 4: filed on 2022-05-06 by TOBIN JAMES R
  • 4: filed on 2022-05-06 by CAREY JOHN F

    • Events (8k)

  • 8-K: filed on 2022-06-02:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-29:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-07:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-15:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-28:
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    51.5 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    3 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RAINES MERILEE

    • Director
    		 13,500 2022-06-01 1

    TOBIN JAMES R

    • Director
    		 13,500 2022-06-01 3

    KANIA EDWIN M JR

    • Director
    		 13,500 2022-06-01 3

    GUNDERSON THOMAS JAMES

    • Director
    		 13,500 2022-06-01 1

    LOVELL STEPHANIE

    • Director
    		 13,500 2022-06-01 1

    BASILE EDWARD M

    • Director
    		 13,500 2022-06-01 1

    WEILL DAVID

    • Director
    		 13,500 2022-06-01 1

    CAREY JOHN F VP OF OPERATIONS

    • Officer
    		 23,868 2022-06-01 10

    KHAYAL TAMER I CHIEF COMMERCIAL OFFICER

    • Officer
    		 52,000 2022-02-22 3

    HASSANEIN WALEED H PRESIDENT & CEO

    • Officer
    • Director
    		 250,000 2022-02-22 2

    PROVOST MIRIAM VP OF GLOBAL REGL. AFFAIRS

    • Officer
    		 38,000 2022-02-22 4

    GORDON STEPHEN CHIEF FINANCIAL OFFICER

    • Officer
    		 52,000 2022-02-22 3

    DAMME LAURA VP, CLINICAL AFFAIRS

    • Officer
    		 38,000 2022-02-22 1

    SULLIVAN JOHN F VP OF QUALITY & ENGINEERING

    • Officer
    		 30,045 2021-08-30 1

    GODHANI RAKESH P. CHIEF DIGITAL OFFICER

    • Officer
    		 0 2021-08-04 2

    ABRAMS CAPITAL MANAGEMENT, L.P.

    ABRAMS CAPITAL MANAGEMENT, LLC

    ABRAMS CAPITAL PARTNERS II, L.P.

    ABRAMS CAPITAL, LLC

    ABRAMS DAVID C

    RIVA CAPITAL PARTNERS III, L.P.

    RIVA CAPITAL MANAGEMENT III, LLC

    • 10% Owner
    		 No longer subject to file 2021-02-08 0

    UNITED THERAPEUTICS CORP

    LUNG BIOTECHNOLOGY PBC

    • 10% Owner
    		 No longer subject to file 2019-12-09 0

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND 2007, L.P.

    AFEYAN NOUBAR

    • 10% Owner
    		 No longer subject to file 2019-10-29 0

    GILBERT JAMES

    • Director
    		 0 2019-05-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-06-03 17:00:25 -0400 2022-06-01 M 1,500 $0.28 a 1,879 direct yes 1.9608 -6.5723 1.9608 2 -6.5723 6

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-06-03 17:00:25 -0400 2022-06-01 S 978 $27.89 d 901 direct yes 1.9608 -6.5723 1.9608 2 -6.5723 6

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-06-03 17:00:25 -0400 2022-06-01 S 522 $28.74 d 379 direct yes 1.9608 -6.5723 1.9608 2 -6.5723 6

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-06-03 17:00:25 -0400 2022-06-01 M 1,500 d 23,489 direct yes

    TOBIN JAMES R - Director

    		2022-06-06 16:28:41 -0400 2022-06-01 A 13,500 a 13,500 direct

    BASILE EDWARD M - Director

    		2022-06-06 16:28:13 -0400 2022-06-01 A 13,500 a 13,500 direct

    WEILL DAVID - Director

    		2022-06-06 16:29:13 -0400 2022-06-01 A 13,500 a 13,500 direct

    LOVELL STEPHANIE - Director

    		2022-06-06 16:29:10 -0400 2022-06-01 A 13,500 a 13,500 direct

    RAINES MERILEE - Director

    		2022-06-06 16:32:42 -0400 2022-06-01 A 13,500 a 13,500 direct

    KANIA EDWIN M JR - Director

    		2022-06-06 16:32:37 -0400 2022-06-01 A 13,500 a 13,500 direct

    GUNDERSON THOMAS JAMES - Director

    		2022-06-06 16:33:44 -0400 2022-06-01 A 13,500 a 13,500 direct

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-05-06 16:05:14 -0400 2022-05-04 M 1,500 $0.28 a 1,879 direct yes -6.9131 1.8484 7.1349 10.4991 15 -8.7246 3

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-05-06 16:05:14 -0400 2022-05-04 S 1,500 $25.31 d 379 direct yes -6.9131 1.8484 7.1349 10.4991 15 -8.7246 3

    CAREY JOHN F - Officer VP OF OPERATIONS

    		2022-05-06 16:05:14 -0400 2022-05-04 M 1,500 d 24,989 direct yes

    TOBIN JAMES R - Director by the james r. tobin 2012 trust

    		2022-05-06 16:05:50 -0400 2022-05-04 S 48,516 $29.94 d 350,621 indirect yes -6.9131 1.8484 7.1349 10.4991 15 -8.7246 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TRANSMEDICS GROUP INC TMDX 2022-06-24 22:15:03 UTC 0.7373 0.8327 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 21:45:03 UTC 0.7373 0.8327 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 21:15:04 UTC 0.7373 0.8327 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 20:45:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 20:15:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 19:45:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 19:15:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 18:45:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 18:15:04 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 17:45:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 17:15:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 16:45:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 16:15:03 UTC 0.722 0.848 450000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 15:45:03 UTC 0.722 0.848 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 15:15:03 UTC 0.722 0.848 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 14:45:03 UTC 0.6695 0.9005 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 14:15:03 UTC 0.6695 0.9005 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 13:45:03 UTC 0.6695 0.9005 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 13:15:03 UTC 0.6695 0.9005 400000
    TRANSMEDICS GROUP INC TMDX 2022-06-24 12:45:03 UTC 0.6695 0.9005 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund TMDX -800.0 shares, $-26544.0 2021-06-30 N-PORT

    Elevate your investments